These findings confirm that EB1089 restores the antiproliferative response of antiestrogens and enhances the inhibitory effects of the combination of lapatinib with antiestrogens in HER2-positive breast cancer cells that lack ERα. This evidence concerns the gene ESR1 and breast cancer.